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ABCG2, a member of the ATP-binding cassette transporters
has been identified as a protective pump against endogenous
and exogenous toxic agents. ABCG2 was shown to be expressed
at high levels in stem cells and variably regulated during cell
differentiation. Here we demonstrate that functional ABCG2 is
expressed in human monocyte-derived dendritic cells by the
activationof anuclear hormone receptor, PPAR.We identified
and characterized a 150-base pair long conserved enhancer
region, containing three functional PPAR response elements
(PPARE), upstream of the human ABCG2 gene. We confirmed
the binding of the PPARRXR heterodimer to this enhancer
region, suggesting that PPAR directly regulates the transcrip-
tion of ABCG2. Consistent with these results, elevated expres-
sionofABCG2mRNAwas coupled to enhancedproteinproduc-
tion, resulting in increased xenobiotic extrusion capacity
via ABCG2 in PPAR-activated cells. Furthermore PPAR
instructed dendritic cells showed increased Hoechst dye extru-
sion and resistance to mitoxantrone. Collectively, these results
uncovered a mechanism by which up-regulation of functional
ABCG2 expression can be achieved via exogenous or endoge-
nous activation of the lipid-activated transcription factor,
PPAR. The increased expression of the promiscuous ABCG2
transporter can significantly modify the xenobiotic and drug
resistance of human myeloid dendritic cells.
The ATP-binding cassette (ABC)2 transporter G2 (ABCG2),
also known as breast cancer resistance protein (BCRP), mitox-
antrone resistance protein (MXR), and ATP-binding cassette
placenta (ABCP), belongs to a transmembrane protein super-
family that mediates the ATP-dependent translocation of a
variety of lipophilic substrates (1–3). Within the human ABC
superfamily, ABCG2 belongs to a group of half-transporters
that consist of six transmembrane spanning domains that
homodimerize to form the active membrane transporter (4).
The ABCG2 gene is highly expressed in the plasma membrane
of several drug-resistant cell lines, where it has been shown to
transport antitumor drugs including mitoxantrone, topotecan,
daunorubicin, and doxorubicin (3, 5, 6). In normal tissues, high
level expression of ABCG2 is found in the placenta and small
intestine, and this protein was shown to play a role in the pro-
tection of the organism against toxic xenobiotics (7). ABCG2 is
also abundantly expressed in various stem cells, characterized
by an increased Hoechst dye efflux capacity (side population,
SP) (8). During hematopoietic differentiation, ABCG2 level is
initially down-regulated, but the protein is expressed again in
some mature cell types e.g. of the erythroid lineage (9). ABCG2
was shown to reduce the accumulation of toxic heme metabo-
lites, thus the pump expression is part of cell survival strategy
under hypoxic conditions (10).
Despite its apparently tight regulation, the molecular details
of ABCG2 gene expression control are poorly defined and
not well understood. A recent report suggested that ABCG2
expression is induced by hypoxia, and this regulation involves
the hypoxia-inducible transcription factor complex HIF-1 (10).
The expression of several ABC transporters is known to be
regulated by nuclear hormone receptors. It was described that
the increased expression of bothABCA1 andABCG1occurs via
the oxysterol-activated nuclear receptor, the liver X receptor
(LXR), in macrophages (11). In addition, in this cell type,
ABCA1 expression is also induced by PPAR activators,
through the activation of LXR receptor (12, 13).
As part of our gene expression profiling efforts of nuclear
receptor-mediated changes in human dendritic cell differenti-
ation and subtype specification, we have identified ABCG2 as a
tightly regulated gene by one of the receptors. Here we report
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Supplemental Material can be found at: 
that PPAR directly and transcriptionally induces ABCG2
expression in a cell type of the human myeloid lineage, mono-
cyte-derived dendritic cells. We have identified and character-
ized the regions of the gene involved in this transcriptional
activation. We also document that dendritic cells activated by
PPAR express high levels of functional ABCG2 protein, and
gain an enhanced capacity to extrude xenobiotics. These fea-
tures may have important consequences to the survival and
drug resistance of human dendritic cells during immune regu-
lation and also have therapeutic ramifications.
EXPERIMENTAL PROCEDURES
Ligands—Rosiglitazone, troglitazone, and T0901317 were
obtained fromAlexis Biochemicals, GW9662 andGW347845X
were provided by T. M. Willson (GlaxoSmithKline, Research
Triangle Park, NC). KO143 was kindly provided by Dr. Gerit-
Jan Koomen, Amsterdam.
Plasmids—Mammalian expression vectors coding human
retinoid X receptor  (RXR), mouse PPAR, -galactosidase,
and thymidine kinase (TK)-Luc were described previously (14).
The identified 150-bp fragment of the genomic region of the
ABCG2 promoter containing 3 response elements was cloned
into TK-Luc to obtain enhancer trap construct.
Transient Transfections and Reporter Gene Assays—TK-Luc
enhancer were transfected along with the indicated receptors.
All transfection experiments were performed with COS1 and
293T cells using jetPEI reagent (Qbiogene) according to the
manufacturer’s instructions. Cells were lysed and assayed for
reporter expression 24 h after transfection. The luciferase assay
system (Promega) was used according to the manufacturer’s
instruction. The -galactosidase activity was determined as
described previously (15). Measurements were made using a
Wallac Victor-2, multilabel counter. Luciferase activity of each
sample was normalized to the -galactosidase activity.
RNA Interference—For siRNA delivery the AMAXANucleo-
fection technology was applied. MM6 cells (1 106) were har-
vested and electroporated with 1.5 g of siRNA using the cell
line nucleofector kit V (AMAXA), program v-001. We used a
previously described PPAR-specific siRNA sequence (16):
GCCCTTCACTACTGTTGAC-d(TT). As a negative control,
Silencer Negative Control 1 siRNA (Ambion) was used.
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation was carried out as described previously (14, 17).
Immunoprecipitationwas performedwith the followingmono-
clonal antibodies: anti-RXR (2ZK8508H; Perseus Proteom-
ics), anti-PPAR (2ZK8713; Perseus Proteomics).
Electrophoretic Mobility Shift Assays (EMSAs)—Electro-
phoretic mobility shift assays were performed as described ear-
lier (14, 18). In brief, full-length, RXR and PPAR receptors
were produced by using the T7 Quick TNT in vitro transcrip-
tion-translation kit (Promega). For supershift experiments, the
receptors were preincubated with the indicated monoclonal
antibodies: anti-RXR (2ZK8508H), anti-PPAR (2ZK8713).
The sequences of oligonucleotides thatwere used are presented
in the supplemental Table S1.
Cell Culture and Ligand Treatment—Monocytes (98%
CD14) were obtained from buffy coats by Ficoll gradient cen-
trifugation and immunomagnetic cell separation using anti-
CD14-conjugated microbeads (VarioMACS, Miltenyi Biotec).
DCswere prepared as described previously (19). In brief,mono-
cytes were resuspended into 6-well culture dishes at a density of
1.5  106 cells/ml and cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (Invitrogen), containing 800
units/ml GM-CSF (Leucomax) and 500 units/ml IL-4 (Pepro-
tech). Cells were cultured for 5 or 6 days (unless otherwise indi-
cated), and the IL-4 and GM-CSF addition was repeated at day
3. Ligands or vehicle control (50%Me2SO/ethanol) were added
to the cell culture from the first day on. MonoMac-6 (MM6)
cells were a kind gift of E. Duda (Biological Research Center,
Szeged, Hungary). These cells were cultured in RPMI 1640 sup-
plemented with 10% fetal bovine serum.
Western Blot Analysis—50 g of protein from whole cell
extract were separated by electrophoresis in 10% polyacrylam-
ide gel and then transferred to polyvinylidene difluoride mem-
brane (Bio-Rad). Membranes were probed with anti-ABCG2
(BXP-21) antibody (Alexis Biochemicals), then stripped and re-
probed with anti-GAPDH antibody (ab8245-100, Abcam).
FACS Analysis—Cell staining was performed using FITC- or
PE-conjugated monoclonal antibodies: Labeled antibodies for
flow cytometry included anti-CD1a-PE, CD1d-PE, CD80-PE,
CD86-PE, and isotype-matched controls (BD PharMingen).
For the ABCG2 detection cells were fixed with 1% paraformal-
dehyde for 5 min, then incubated with unlabeled anti-ABCG2
(5D3) or isotype-matched control (R and D system) antibody
for 30 min at 37 °C, followed by staining with FITC-labeled
anti-mouse antibody (BD PharMingen). The fluorescence of
labeled cells was measured using a FACSCalibur flow cytome-
ter (Beckton Dickinson).
Real-time RT-PCR—Total RNA was isolated with TRIzol
reagent (Invitrogen). Reverse transcription was performed at
42 °C for 1 h and 72 °C for 5min from 100–200 ng of total RNA
using Superscript II reverse transcriptase (Invitrogen). Quanti-
tative PCR was performed using real-time PCR (ABI PRISM
7900, Applied Biosystems): 40 cycles at 95 °C for 12 s and 60 °C
for 30 s using Taqman assays. All PCR reactions were done in
triplicate with one control reaction containing cDNA that was
reverse transcribed without RT enzyme. The comparative Ct
method was used to quantify transcripts, and the expression
levelwas normalized to 36B4or cyclophilinA.The sequences of
the primers and probes are presented in supplemental Table S1.
Measurement of Hoechst Retention by Confocal Laser-scanning
Microscopy and FACS—DCs were plated on Lab-Tek coverslip
chambers. Cells were incubated with 0.5 g/ml Hoechst 33342
for 1 h at 37 °Cwith orwithout KO143 (1M), then subjected to
microscopic analysis. Hoechst fluorescence was measured on a
Zeiss LSM 510 confocal microscope with a Plan-Apochromat
60 (NA 1.4) oil immersion objective using maximal detection
pinhole diameter (1 mm) to get signal from the whole depth of
the nucleus. Hoechst was excited by the 351 and 364 nm lines of
an Argon ion laser, emission was measured through a 385–
470-nm bandpass filter.
Hoechst content was also measured on a Becton Dickinson
FACSVantage flow cytometer. Hoechst fluorescence was
excited by 351- and 364-nm lines, and the blue and redHoechst
signals were detected through 402–446-nm and 650-nm fil-
ters, respectively.
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Measurement of Mitoxantrone Uptake by FACS Analyses—
Cells were resuspended in phenol red-free HPMI medium con-
taining the desired fluorescent compound (5 M mitoxantrone)
with orwithoutKO143 (1M) and incubated at 37 °C for 30min,
Thereafter, the cells were washed
with cold HPMI and subjected to
flow cytometric analyses. The cells
were assessed for fluorescence inten-
sity with a FACSCalibur cytometer
(Beckton Dickinson).
Cytotoxicity Assay—Cytotoxicity
assays were carried out using the
MTT (3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyl-tetrazolium bromide)
assay. Briefly, cells were plated in
96-well plates at a density of 105 cells
per well. Mitoxantrone at vari-
ous concentrations with or without
KO143 was added to DCs, and cells
were incubatedat 37 °C for48h.After
incubation, cytotoxicity was assessed
by using the MTT assay. The MTT
assay was performed as described
previously (20) and as specified by
ATCC.
Statistical Analyses—Values are ex-
pressed as mean  S.D. of the mean.
Significant differences between mean
values were evaluated using two-tailed,
unpaired Student’s t test.
RESULTS
ABCG2 Is Highly and Selectively
Induced by PPAR Agonists in
HumanDendritic Cells—Previously
we have characterized the role of
PPAR nuclear receptor in mono-
cyte-derived dendritic cell (DC) dif-
ferentiation (19). We observed that
PPAR was acutely and rapidly up-
regulated during DC differentiation
and acted as a modifier of DC gene
expression and function. This cellu-
lar system is particularly suitable to
identify PPAR responsive genes
because the bona fide PPAR target,
the fatty acid-binding protein 4
(FABP4 also known as aP2) was
highly induced (50–100-fold) upon
PPAR agonist treatment. We
sought to identify direct targets of
PPAR with expression pattern
similar to that of FABP4 using
global gene expression analysis
(Affymetrix Microarrays). One of
the candidate genes matching these
criteria was an ABC half-trans-
porter, ABCG2. To validate the
microarray data, the transcript level of ABCG2was determined
by real-time quantitative RT-PCR (RT-Q-PCR) from RNAs
obtained from monocytes and monocyte-derived human DCs.
When compared the expression of FABP4 to ABCG2 a similar
FIGURE 1. PPAR ligand treatment up-regulates the expression of ABCG2. A, FABP4 and ABCG2 transcript
is highly up-regulated in PPAR ligand-treated DCs. Transcript levels were determined frommonocytes (MC),
vehicle or PPAR ligand-treated DCs (2.5 M RSG) alone or with a PPAR-specific antagonist (ANT): 5 M
GW9662 by RT-Q-PCR. Gene expression data are expressed as a ratio of FABP4 or ABCG2 transcripts relative to
36B4 expression  S.D. Data were obtained from three individuals. B, transcript levels of ABCG2 and FABP4
weredetermined inDC treatedwith various ligands: 2.5MRSG, 100nMGW347845X (abbreviated asGW7845),
1M troglitazone (TRO). C, expression of FABP4 and ABCG2 is impaired in PPAR knock-downMM6 cells. MM6
cells were electroporated with a control or PPAR-specific siRNA as described under “Experimental Proce-
dures.” After electroporation MM6 cells were cultured for 12 h; thereafter cells were treated with 2.5 M RSG
alone or alongwith an RXR agonist (LG, 100 nM LG268) and cultured for 24 h. Transcript levels of FABP4, ABCG2,
PPAR, and PPARwere determined by RT-Q-PCR.
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FIGURE 2. ABCG2 is regulated by PPAR via a mechanism independent of LXR. A, mRNA levels of ABCA1, ABCG1, and ABCG2 were determined with
RT-Q-PCR. Cells were cultured for 24 h and treated with 1M RSG or with an LXR-specific ligand: 1M T0901317 (T09). B, dose-dependent induction of FABP4
and ABCG2. Cells were treated with the indicated concentration of RSG; the mRNA expression was determined by RT-Q-PCR. C, kinetics of FABP4 and ABCG2
induction. Cells were cultured for 12 h; thereafter cells were treated with 1 M RSG and harvested at the indicated time points and the mRNA expression was
determined by RT-Q-PCR.
FIGURE 3. Identification of PPARRXR binding sites in the human ABCG2 gene. A, sequence of a portion of the human ABCG2 upstream region (3946/
3796 bp), highlighting the three putative PPAR responsive elements (A, B, and C elements). B, EMSA was carried out by using in vitro-translated receptors of
PPAR, RXR, and-32P-labeled oligonucleotides as described under “Experimental Procedures.” For competition experiments, cold (ColdWT), mutated (Cold
MUT) or consensus DR1 oligonucleotides were used at10 and20 concentrations. For supershift experiments, the receptors were preincubated with the
indicated antibodies prior to the binding reaction.
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pattern ofmRNA levels was observed (Fig. 1A). Consistent with
themicroarray data, PPAR agonist (rosiglitazone, abbreviated
as RSG) treatment highly enhanced the expression of both
genes. Although rosiglitazone is a specific PPAR agonist, its
ability to induce ABCG2 in developing DCs still may be related
to other pharmacologic activities. To address this issue a
PPAR antagonist (GW9662) was simultaneously added to the
cells. As shown in Fig. 1A, administration of the antagonist
(ANT) abolished the induction of
ABCG2 suggesting that this regula-
tion is indeed PPAR receptor-de-
pendent. We used other chemically
distinct synthetic PPAR agonists
to further establish the receptor
specificity of ABCG2 induction.
Cells were treated with troglita-
zone (TRO) or with GW347845X
(abbreviated as GW7845). As
shown in Fig. 1B, all of these
PPAR activators induced FABP4
and ABCG2 expression.
Up-regulation ofABCG2was also
detected in a monocytic/macro-
phage leukemia cell line (Monomac
6, abbreviated as MM6) by the acti-
vation of the PPARRXR het-
erodimer (Fig. 1C). PPAR forms a
heterodimer with the RXR receptor.
Interestingly, in MM6 cells both
components of the heterodimer
had to be activated to elicit a pro-
found ABCG2 expression induction
(MM6 cells were simultaneous
treatedwith 2.5MRSG and 100 nM
LG268, an RXR agonist). To further
establish the role of PPAR in
ABCG2 regulation, we used RNA
interference to suppress the expres-
sion of PPAR in MM6 cells. We
used a previously described (16)
PPAR-specific siRNA that effec-
tively inhibited the expression of
endogenous PPAR but it did not
interfere with expression of PPAR
(Fig. 1C). Significantly, PPAR-spe-
cific siRNA-treated cells showed
impaired induction of FABP4 and
ABCG2, indicating that the tran-
scriptional induction of these genes
are receptor-dependent. Taken to-
gether, these results demonstrate
that activation of PPAR induces
elevated ABCG2 mRNA expression
both in DCs and in the myeloid leu-
kemia cell lineMM6.Moreover, this
regulation appears to be selectively
PPAR receptor dependent in both
cell types.
ABCG2 Is Regulated by PPAR via a Mechanism Independ-
ent of LXR—It has been documented that, under certain condi-
tions, PPAR can indirectly activate gene expression by the
induction of its direct target receptor, LXR. For example,
ABCA1 expression is regulated via such a mechanism (12, 13).
A previous study has also established that ABCA1 and ABCG1
are direct target genes of LXRs (11). We also observed that a
PPAR ligand enhances the expression of LXR in DCs (data
FIGURE 4. An upstream sequence of the human ABCG2 gene, containing three DR1s, is able to promote
transcription in a PPAR-dependent manner in a cell based binding assay. A, COS1 or 293T cells were
cotransfected with TK-Luc or with TK-Luc enhancer, the VP16 fusion protein of PPAR with or without RXR,
and-galactosidase. Cellswere lysed after 24h, and the luciferase and-galactosidase activitywere assayedas
described under “Experimental Procedures.” All experiments were done in triplicates S.D. B, COS1 cells were
cotransfected with the indicated nuclear receptors, TK-Luc enhancer or with luciferase reporter construct
containing 3 PPAR responsive elements (3PPRE) and-galactosidase. The indicated cells were treatedwith 1
M RSG. C, ChIP was performed with anti-RXR and anti-PPAR antibodies using chromatin obtained from
RXR- or PPAR-transduced 293T cells, respectively. DNA content was analyzedwith RT-Q-PCR assays specific
for the genomic region of LXR containing a PPRE, the identified ABCG2 enhancer region and a genomic
region of the 36B4 gene. The results are shown as percentages of input DNA. All measurements were done in
triplicate. As a negative control no-antibody control (NAB) was used.
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not shown) suggesting that an LXR-dependent pathwaymay be
responsible for the up-regulation of certain ABC transporters.
To examine if the activation of PPAR enhances ABCG2
transcription via the induction of LXR, we compared the
effects of PPAR and LXR agonists on the mRNA levels of
ABCA1, ABCG1, and ABCG2 by RT-Q-PCR. As shown in Fig.
2A, we found that in this cell type the activation of PPAR failed
to induceABCA1 andABCG1 expression, whereas we detected
a profound up-regulation of these transporter mRNAs if cells
were treated with an LXR-specific agonist (T0901317). In con-
trast to ABCA1 and ABCG1, T0901317 did not affect the
expression of ABCG2. These data indicate that in human DCs
ABCG2 regulation is independent from LXR induction/acti-
vation, and in these cells the selective activation of nuclear hor-
mone receptors results in a non-overlapping ABCA1-ABCG1
versus ABCG2 expression pattern.
PPAR Directly Regulates the Transcription of the ABCG2
Gene—Our results demonstrated that themRNA expression of
ABCG2 is positively regulated by PPAR-specific ligands in a
receptor-dependent manner. Next, we have examined the dose
and time dependence of ABCG2 induction. PPAR activators
(for example rosiglitazone) belong to a class of antidiabetic
compounds (thiazolidinediones), that are used in the clinic to
treat type II diabetes (21). The plasma concentration of RSG in
patients treated with 4 mg of RSG is between 50–350 ng/ml
(100–1000 nM) (22). To examine whether ABCG2 can be acti-
vated ex vivo in this concentration range, we performed dose
response experiments. As shown in Fig. 2B, 100 nM RSG readily
induced the expression of ABCG2, suggesting that this gene is
likely to be induced in DCs in vivo upon RSG treatment.
Next we asked whether the activa-
tion of PPAR directly elicits the
accumulation of ABCG2 transcripts.
Time course experiments (Fig. 2C)
revealed that ABCG2 similarly to
FABP4 were rapidly up-regulated
upon PPAR ligand administration.
Although this finding is not a proof in
itself, it strongly suggests that PPAR
directly regulates the expression of
ABCG2.
To further test this possibility, we
analyzed the promoter sequence of
the ABCG2 gene to find putative
PPAR responsive elements. The
sequence analysis of the previously
reported promoter region (1285/
362) of the human ABCG2 gene
(10) did not reveal any canonical
PPAR response elements. Further-
more transient transfection assays
carried out to assess the activity of
this promoter region (1285/362)
failed to indicate anyPPAR-depend-
ent transcriptional response (data not
shown). Therefore we decided to use
a bioinformatics approach for the
identification of conserved promoter
regions and putative PPAREs. The ABCG2 protein is relatively
well conserved in evolutionary distant animals.However the com-
pletely untranslated first exon shows very little similarity between
species, thus the identification of the promoter region is rather
difficult. In addition several species such as the mouse and rat
containparalogousABCG2 geneswith alternatively spliced 5-un-
translated region (UTR) exon(s). Using cDNA sequences to iden-
tify the first UTR exons we have succeeded in finding putative
promoter regions of bovine and dog ABCG2 genes beside the
almost identical primate sequences. Comparison of 5000 base
pairsofhuman,dog, andbovineABCG2promoter regions (count-
ing from the position of the beginning of the 5 longest cDNA
sequence) revealed awell conserved region (supplemental Fig. S1).
We have identified a 150-bp portion (3946/3796) of this con-
served region, which contains three potential PPAR response ele-
ments in the human and one in bovine and dog (Fig. 3A and sup-
plemental Fig. S1). To test the ability of these elements for binding
PPARRXR in vitro, we carried out EMSA. The EMSA analysis
revealed that all threeputative elements, containingdirect repeat1
(DR1, AGGTCANAGGTCA) motifs, were able to specifically
bindPPARRXRheterodimers (Fig. 3B). In these experimentswe
also found that if the two receptors were added together, a stron-
ger, specific binding was observed. This binding was effectively
competed by either unlabeled (cold) oligos, or a canonical DR1
oligonucleotide, but not with oligonucleotides containing muta-
tions. The specificity of the binding was further demonstrated by
the use of antibodies against RXR and PPAR, which induced
marked supershifts (Fig. 3B). Next an enhancer trap method was
employed toassess thebindingand transcriptionactivationcapac-
ity of these elements. We introduced the identified element
FIGURE 5.ABCG2 protein is expressed in PPAR-instructed DCs. A, Western blot analysis of ABCG2 protein
expression in differentiating DC. 50g of cell extract (monocyte-MC, the indicated cells were treated with 2.5
M RSG) were subjected to Western blot analysis, the identity of the 70-kDa bands was confirmed by co-
migrationwith a band seen in the extract (2g) of ABCG2-transfected 293T cells.GAPDHwas used as a loading
control. B, determination of the cell surface expression of ABCG2 in DCs. Control or ligand-treated cells were
fixed and stained with an unlabeled anti-ABCG2 (5D3) or isotype-matched control and after 30min of incuba-
tion with anti-mouse FITC-labeled antibody. Cell surface molecule specific antibodies indicated (solid line)
versus isotype-matched control (dotted line). Cells were treated with 2.5 M RSG alone or RSG plus a PPAR
antagonist (ANT, GW9662).
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(3946/3796) into a reporter plasmid upstream of theminimal
TK-luciferase promoter, generating the heterologous promoter
construct termed ABCG2enhancer-TK-Luc (TK-Luc ENH). To
determine the receptor binding capacity of the enhancer region in
a cellular system,we co-transfected theABCG2enhancer-TK-Luc
reporter construct with the expression vector, containing consti-
tutively active PPAR (VP16-PPAR) alone or VP16-PPAR
alongwithRXR.Weobtainedarobust inductionof reportergene
activitywhen the cellswere cotransfectedwithVP16-PPAR, and,
as anticipated, the inductionwas further increased in the presence
ofRXR (Fig. 4A).Weobtained similar results in two independent
cell lines (COS1and293T). In a specificity control experiment, the
TK-Luc dependent transcription was not modified by receptor
expression in the absence of the enhancer region. These data pro-
vided evidence for a possible in vivo binding of the receptor het-
erodimer to the identified enhancer elements in theABCG2 gene.
To test this role directly, COS1 cells were co-transfectedwith
the ABCG2enhancer-TK-Luc reporter construct, along with
expression vectors coding for PPAR or RXR in various com-
binations (Fig. 4B). We observed that the presence of the
PPARRXR heterodimer induced a major transcription
response, and this was further elevated by the administration of
a PPAR-specific ligand, RSG. We also included a promoter
element containing canonical PPAR responsive elements
(3PPRE) as a positive control (Fig. 4B). Finally, we analyzed if
PPAR and RXR protein was bound to the ABCG2 enhancer
region in cells using chromatin immunoprecipitation (ChIP)
combined with real-time PCR. Chromatin was obtained from
PPAR- or RXR-transduced 293T cells. A genomic region of
the LXR gene containing a PPRE element was used as a posi-
tive control and a genomic region of the 36B4 genewas tested as
a negative control. Consistent with EMSA and the transient
transfection results, our analyses demonstrated that both
PPAR andRXRwere present on theABCG2 enhancer region
also in the chromatin context (Fig. 4C).
Taken together, all these data strongly suggest that the genomic
region examined, upstream of the ABCG2 coding sequence, can
bind PPARRXR heterodimers, and this enhancer region is able
to confer a PPAR-dependent transcriptional response. Thus this
genomic region most likely participates in the PPAR-dependent
regulation of ABCG2 expression.
ABCG2 Protein Expression Is Up-regulated in PPAR-acti-
vated Cells—Our results described above suggest that PPAR
directly and specifically induces the mRNA expression of
FIGURE 6. Enhanced efflux of Hoechst 33342 in DCs upon PPAR activation. A, cells were incubated with 0.5 g/ml Hoechst dye for 1 h at 37 °C with or
without KO143 (1 M), then subjected to microscopic analysis as described under “Experimental Procedures.” B, same samples were quantitatively analyzed
with a Becton Dickinson FACSVantage flow cytometer.
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ABCG2 in monocyte-derived DCs. To estimate the changes
in the protein level and the cell surface expression of ABCG2 in
DCs, we performed antibody staining in Western blot and in
flow cytometry experiments. By using the BXP 21, ABCG2-
specificmonoclonal antibody inWestern blotting, we could not
detect the ABCG2 protein either in human monocytes or
untreated DCs. However, a specific 70-kDa protein product
appeared on the immunoblot when human DCs were pre-
treatedwith a PPAR ligand, RSG (Fig. 5A).Wehave also deter-
mined the cell surface expression of the ABCG2 protein by flow
cytometry (Fig. 5B), using the 5D3monoclonal antibody, which
reacts with an extracellular epitope of the transporter. Consist-
ent with the mRNA expression and Western blot data, signifi-
cant cell surface expression of the ABCG2 protein was detected
only in the RSG-treated DCs, whereas this expression was
reduced if the cells were treated with a PPAR antagonist
(GW9662). All these data clearly indicate that PPAR-depend-
ent activation of transcription results in an enhanced ABCG2
protein production, which is correctly processed to reach the
cell membrane surface in DCs. Next we investigated the func-
tional consequences of the elevated level of this xenobiotic
transporter on DCs.
PPAR-instructed DCs Have an Enhanced Capacity to
Extrude Xenobiotics and Acquire Resistance against Anticancer
Agents—The ABCG2 transporter has a wide substrate recogni-
tion and transport capacity and, by performing an efficient
extrusion of the Hoechst 33342 flu-
orescent dye, the expression of
ABCG2 has been implicated in the
so called side population phenotype
of stem cells (8, 23). With the aim of
correlating ABCG2 expression level
and the function of this transporter,
Hoechst 33342 dye accumulation
was compared in normal and PPAR
agonist-treated DCs, respectively.
We have monitored the nuclear
Hoechst dye fluorescence with con-
focal microscopy and flow cytom-
etry analyses. As shown in Fig. 6, A
and B, most of the PPAR-activated
DCs accumulated less Hoechst dye
than the non-stimulated control
cells, indicating an enhanced pump
activity of ABCG2. To assess the
specificity of the assay, KO143, a
specific and selective inhibitor of
ABCG2, was added to block the
transporter activity. We found that
the reduced accumulation of the
fluorescent dye in the stimulated
DCswasABCG2-dependent,because
the administration of KO143 abol-
ished the effect of the PPAR ligand
treatment. Next we assessed the
mitoxantrone (MX) efflux capacity
of the PPAR-activated DCs. As
shown in Fig. 7A, mitoxantrone
accumulation was rapid in the control DCs, whereas after the
addition of the PPAR activator RSG, the cells accumulated less
mitoxantrone than the control DCs. Similarly to that found in
the Hoechst dye uptake studies, mitoxantrone extrusion by
ABCG2 in the activated cells was fully inhibited by the specific
inhibitor of the pump, KO143. Next we examined whether the
presence of ABCG2 in RSG treated DCs conferred a protective
effect against the cytotoxic drug, mitoxantrone. DCs were
treated with different doses of mitoxantrone for 48 h and then
cell viability was assessed by MTT assay. As shown in Fig. 7B,
whereas low doses of MX-induced cell death in the control
DCs, the PPAR ligand-treated DCs were significantly less sen-
sitive to this cytotoxic agent. The addition of ABCG2 inhibitor
KO143 removed this protective effect. In agreement with the
enhanced expression of ABCG2 after PPAR activation of DCs,
the observed reduced Hoechst dye and drug accumulation, as
well as the reduced sensitivity toMX in these cells indicate that
ABCG2 is fully functional, and activated DCs acquire a protec-
tion against cytotoxic agents.
Blocking of ABCG2 Only Mildly Modified the DC Phenotype—
Our results suggest that PPAR-activated DCs have an
enhanced transport capacity to extrude various chemically syn-
thesized drugs. It is an intriguing question, what is the physio-
logical role of this transporter on DCs. To further assess the
functional consequence of the elevated expression of ABCG2,
including its effect on gene expression, we cultured the PPAR-
FIGURE 7. PPAR-activated DCs have an enhanced viability upon mitoxantrone exposure. A, efflux of
mitoxantrone by ABCG2 in DCs. Cells were incubated with 5Mmitoxantrone in the presence or absence of 1
M ABCG2 inhibitor (KO143) for 30 min and washed with ice-cold phosphate-buffered saline, and finally the
intracellular accumulation ofmitoxantronewas assessed by flow cytometry. B, control or PPAR-activated (2.5
MRSG)DCswere cultured for 48 h and treatedwith 1.25 orwith 2.5g/mlmitoxantrone. Cell cytotoxicitywas
assessed with the MTT assay as described under “Experimental Procedures.” **, p 0.01; ***, p 0.001.
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activated cells in the presence of ABCG2 inhibitor (KO143) and
compared the phenotype of the inhibitor-treated and control
cells.We and others (19, 24, 25) have recently characterized the
phenotype of the PPAR-instructed DCs. Consistent with the
previous findings, PPAR-activatedDCs expressedmoreCD86
and CD1d, but the expression of CD80 and CD1a were
decreased (Fig. 8A). The administration of the selective ABCG2
inhibitor (KO143) did not change the cell surface expression of
CD80, CD86, or CD1d but the expression of CD1a was slightly
decreased on the PPAR activated cells (Fig. 8A). We also
assessed the mRNA expression of CD1a and FABP4 by RT-Q-
PCR. The transcript level of FABP4 did not change but CD1a
expression was reduced consistent with the changes detected
on the cell surface expression. Together our data indicate that
blocking the ABCG2 transporter in PPAR-instructed DCs
only mildly modify the phenotype of DCs and it is unlikely that
it contributes significantly to PPAR-dependent changes inDC
phenotype. However, a subset of PPAR-regulated genes (i.e.
CD1a) was slightly modified when the pump was inhibited.
This raises the issues that ABCG2 might have some regulatory
roles in DCs besides its established cytoprotective function,
which is likely to be part of an adaptive response.
DISCUSSION
The functional and adaptive specification of human DCs is a
well established concept (26, 27). However the regulatory pro-
cesses and themolecular underpinnings of functional plasticity
or subtype specifications are largely unknown. Previously we
and others (19, 24, 25) have provided evidence that nuclear
hormone receptors are likely to contribute to these processes.
Here we further characterize the role of one of the lipid-
regulated transcription factors and provide evidence for the
induction of the expression of functional ABCG2 transporter
by PPAR receptor in human monocyte-derived DCs. We
demonstrate the up-regulation of the transporter both at the
mRNAand the protein level, the proper cell surface localization
as well as the xenobiotic transport activity of the pump.
Moreover, we identify a specific enhancer region containing
three PPAREs, directly binding PPAR, in the upstream
region of the ABCG2 gene.
A key issue in regulatory processes especially involving xeno-
biotics response is specificity.We found that ABCG2 induction
was receptor and subtype specific. Neither LXR ligands nor
retinoids (data not shown), regulators of other transporters,
induced the expression of this pump. We also obtained poor
responses when cells were treated with PPAR or PPAR
ligands (data not shown). Furthermore, ABCG2 induction was
abrogated by the addition of a PPAR specific antagonist and by
using siRNA against PPAR. Importantly, the PPAR-depend-
ent regulation appears to be direct. Three PPAR response ele-
ments (direct repeat 1, DR1) were identified and characterized
in the upstream region of the human ABCG2 gene. Gel-shift
and transient transfection analyses as well as chromatin immu-
noprecipitation confirmed the specific binding of PPARRXR
heterodimer to this enhancer region. By the identification of
this upstream enhancer we provide novel insights into the pro-
moter/enhancer structure and regulation of ABCG2 as well.
Earlier studies identified several Sp1 sites in the 222 bp to
49 bp promoter region of ABCG2, a CCAAT-box is also pres-
ent in the 274-bp position, and CpG islands are found in its
downstream proximity (28). In addition, a novel Estrogen
Response Element (ERE) has been identified in the188-bp to
172-bp segment, which triggers an enhanced transcription of
human ABCG2 in ER-positive cells (29). Our data indicate the
presence of a relatively distant (3946/3796 bp) major regu-
latory site, responsible for PPARRXR regulation of this gene.
It is also possible that this conserved enhancer contains other
binding sites, which might contribute to gene regulation. This
issue requires further investigation.
The PPAR-dependent up-regulation of ABCG2 is not
restricted to DCs. It was also detected in the monocyte/macro-
phage cell line, MM6. It is an intriguing question whether this
regulation is a DC and/or at least myeloid cell type-specific
phenomenon, or ABCG2 can be induced in other PPAR-pos-
itive cell types as well. In our preliminary experiments, by using
monocytes cultured with M-CSF, we obtained only a slight
FABP4 induction indicating a weak PPAR response in macro-
phages and failed to detect any ABCG2 induction (data not
shown).Our data still raise the possibility, that in PPAR recep-
tor positive tumor cells activation of this receptormay cause the
appearance of a multidrug resistance phenotype, because of
ABCG2 overexpression. There would be obvious therapeutic
ramifications if this scenario proved to be true. The expression
of ABCG2 is clearly associated with the modulation of xenobi-
otic absorption, distribution, and toxicity in many different tis-
sues. The wide substrate specificity and tissue distribution of
this active transporter thus plays amajor role in pharmacother-
apy. In hematopoietic stem cells the side population (SP) phe-
notype, based on Hoechst 33342 efflux, is provided by a high
level ABCG2 expression.More recently, pheophorbideA, PPIX
and heme have all been shown to be ABCG2 substrates, indi-
cating a role for this protein in the cytoprotection of stem cells
and erythrocytes (9, 30).Our experiments fully support this role
in dendritic cells by showing that PPAR-activated DCs accu-
mulated less Hoechst dye and mitoxantrone. This effect was
reverted by a specific and selective ABCG2 inhibitor, indicating
that the effect is ABCG2-dependent. Consistent with the
enhanced mitoxantrone efflux, we also found that PPAR-
treated DCs showed an increased resistance to the anti-neo-
plastic and immunosuppressive drug, mitoxantrone. Again,
this effect was caused by the function of enhanced ABCG2
expression and activity. Therefore this pathway, if activated,
arms the DCs with the capacity to withstand xenobiotic and
FIGURE 8. Inhibition of ABCG2 activity slightlymodifies expression of CD1a. A, characterization of CD1a, CD1d, CD80, and CD86 cell surface expression on
DCs treated with ligands: 2.5 M RSG alone or with 1 M ABCG2 inhibitor (KO143). Data obtained with specific antibodies indicated (solid line) versus isotype-
matched control (dotted line). B, CD1a and FABP4 transcripts levels were determined fromvehicle or PPAR ligand-treatedDCs (2.5MRSG) alone orwith 1M
ABCG2 inhibitor (KO143). Gene expression data are expressed as a ratio of CD1a and FABP4 transcripts relative to cyclophilin A (cyclo) expression  S.D.
***, p 0.001.
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toxic noxa. Interestingly, it has been shown that PPAR ligand
treatment induced the expression of an UDP-glucuronosyl-
transferase (UGT1A9) in human hepatocytes andmacrophages
(31). UGTs catalyze the glucuronidation reaction, which is a
major pathway in the catabolism and elimination of numerous
xenobiotics. These results suggest that in PPARhas the poten-
tial to coordinately regulate both the inactivation and elimina-
tion of xenobiotics and thus protects these cells. Recently,
tumor antigen-loaded DCs have been introduced to elicit an
anticancer immune response as part of cell therapy protocols.
DC therapy is often combined with chemotherapy. Our results
suggest that the application of a PPAR ligand may protect the
antigen presenting cells by selective induction of ABCG2
expression. The findings reported here may prove to be useful
in designing more efficient cell therapy protocols. Obviously,
this activation should only be utilized in the case of PPAR
negative tumor cells, as PPAR activatorsmay elicit anABCG2-
dependent multidrug resistance in the tumor cells as well. It
remains to be defined how this mechanism contributes to DC
function and activity. It is also not clear what is the function of
this pathway under normal, non-pathological conditions. In
macrophage ABCA1 and ABCG1 have an important role in the
efflux of cholesterol (11, 13). It is a debated issue whether
ABCG2 can transport any lipids. It was reported that ABCG2
mediated the efflux of cholesterol on bacterial cell membrane
(32) but unlike some other members of the ABCG subfamily,
ABCG2 seems not to be critically involved in lipid metabolism,
because in ABCG2-deficient mice, the plasma levels of choles-
terol and phospholipids were normal (30). We failed to detect
any enhanced cholesterol efflux on PPAR activated mono-
cyte-derivedDCs (data not shown).Othermultidrug transport-
ers have roles in enhanced DC transmigration and leukotri-
ene production (33, 34). These data prompted us to investigate
the effect of blocked ABCG2 activity in PPAR-activated cells.
We did not detect major changes in DC phenotype. However,
we observed that in the presence of the ABCG2 inhibitor DCs
expressed less CD1a. Previous results showed that PPAR acti-
vators negatively regulate CD1a (19, 25), therefore it is formally
possible that regulated ABCG2 expression contributes to this
by exporting signaling molecules. It is also possible that certain
PPAR ligands might be transported by ABCG2 providing a
negative feedback regulation to ligand responsiveness. How-
ever we do not have any data to support this scenario yet.
In summary, our study revealed that PPAR-activated DCs
express an increased level of functional ABCG2 transporter,
and these cells acquire relative protection against endo- and
xenobiotics. This activationmay have a significant effect on the
differentiation or drug-dependent modulation of DC function
and may also have therapeutic ramification.
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